William P.  Sheridan net worth and biography

William Sheridan Biography and Net Worth

Dr. William P. Sheridan serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Sheridan joined BioCryst in July 2008 as its Senior Vice President and Chief Medical Officer. Dr. Sheridan spent 15 years in drug development at Amgen Pharmaceuticals, Inc., most recently as Vice President of North American Medical Affairs from March 2007 to November 2007, prior to joining the Company. Dr. Sheridan organized and led Amgen’s U.S. Medical Affairs function, making significant contributions to the successful launch of many compounds, including Aranesp®, Enbrel®, Kineret®, Neulasta® and Sensipar®. In addition to his most recent position at Amgen, Dr. Sheridan served at the Vice President level in International Medical Affairs, from March 2005 to February 2007; Global Health Economics, from January 2004 to January 2005; and Outcomes Research, U.S. Medical Affairs and Product Development from January 2002 to December 2003. Prior to joining Amgen, Dr. Sheridan practiced medicine at the Royal Melbourne Hospital in Victoria, Australia as Head of the Bone Marrow Transplant Service. He earned his MB BS degree (M.D. equivalent) at the University of Melbourne in Victoria. He is a board-certified fellow of the Royal Australasian College of Physicians, with a sub-specialty in hematology and medical oncology. After leaving Amgen in November 2007 and prior to joining the Company, Dr. Sheridan served as an independent consultant for pharmaceutical companies, including BioCryst.

What is William P. Sheridan's net worth?

The estimated net worth of William P. Sheridan is at least $224,379.46 as of May 27th, 2021. Dr. Sheridan owns 39,434 shares of BioCryst Pharmaceuticals stock worth more than $224,379 as of December 10th. This net worth estimate does not reflect any other investments that Dr. Sheridan may own. Additionally, Dr. Sheridan receives an annual salary of $784,090.00 as Insider at BioCryst Pharmaceuticals. Learn More about William P. Sheridan's net worth.

How old is William P. Sheridan?

Dr. Sheridan is currently 68 years old. There are 8 older executives and no younger executives at BioCryst Pharmaceuticals. The oldest executive at BioCryst Pharmaceuticals is Dr. Yarlagadda S. Babu, Chief Discovery Officer, who is 70 years old. Learn More on William P. Sheridan's age.

What is William P. Sheridan's salary?

As the Insider of BioCryst Pharmaceuticals, Inc., Dr. Sheridan earns $784,090.00 per year. There are 2 executives that earn more than Dr. Sheridan. The highest earning executive at BioCryst Pharmaceuticals is Mr. Jon P. Stonehouse, CEO, President & Executive Director, who commands a salary of $1,150,000.00 per year. Learn More on William P. Sheridan's salary.

How do I contact William P. Sheridan?

The corporate mailing address for Dr. Sheridan and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at [email protected]. Learn More on William P. Sheridan's contact information.

Has William P. Sheridan been buying or selling shares of BioCryst Pharmaceuticals?

William P. Sheridan has not been actively trading shares of BioCryst Pharmaceuticals during the past quarter. Most recently, William P. Sheridan sold 71,759 shares of the business's stock in a transaction on Thursday, May 27th. The shares were sold at an average price of $15.00, for a transaction totalling $1,076,385.00. Following the completion of the sale, the insider now directly owns 39,434 shares of the company's stock, valued at $591,510. Learn More on William P. Sheridan's trading history.

Who are BioCryst Pharmaceuticals' active insiders?

BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Nancy Hutson (Director), Vincent Milano (Director), William Sheridan (Insider), and Jon Stonehouse (CEO). Learn More on BioCryst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of BioCryst Pharmaceuticals?

During the last twelve months, insiders at the biotechnology company sold shares 6 times. They sold a total of 127,370 shares worth more than $1,324,621.75. The most recent insider tranaction occured on June, 15th when Director Machelle Sanders sold 4,000 shares worth more than $31,920.00. Insiders at BioCryst Pharmaceuticals own 4.4% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.

Information on this page was last updated on 6/15/2023.

William P. Sheridan Insider Trading History at BioCryst Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/27/2021Sell71,759$15.00$1,076,385.0039,434View SEC Filing Icon  
12/18/2018Sell20,488$7.58$155,299.042,725View SEC Filing Icon  
8/9/2018Sell62,500$7.03$439,375.0085,713View SEC Filing Icon  
6/1/2018Sell42,112$6.30$265,305.6063,170View SEC Filing Icon  
11/13/2017Sell64,310$4.72$303,543.20View SEC Filing Icon  
6/19/2015Sell70,389$15.05$1,059,354.45View SEC Filing Icon  
12/30/2014Sell128,399$12.36$1,587,011.64View SEC Filing Icon  
12/29/2014Sell105,295$12.43$1,308,816.85View SEC Filing Icon  
See Full Table

William P. Sheridan Buying and Selling Activity at BioCryst Pharmaceuticals

This chart shows William P Sheridan's buying and selling at BioCryst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals logo
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $5.69
Low: $5.59
High: $5.82

50 Day Range

MA: $5.73
Low: $4.98
High: $6.77

2 Week Range

Now: $5.69
Low: $4.82
High: $12.07


5,120,367 shs

Average Volume

3,669,082 shs

Market Capitalization

$1.17 billion

P/E Ratio


Dividend Yield